Comprehensive Dermatologic Drug Therapy

Part I: Introduction

1 Basic Principles of Pharmacology

2 Principles for Maximizing the Safety of Dermatologic Drug Therapy

3 Polymorphisms: Why Individual Drug Responses Vary

4 Adherence to Drug Therapy

5 Medical Decision Making

Part II: Important Drug Regulatory Issues

6 The FDA Drug Approval Process

7 Pharmacovigilance: Verifying that Drugs Remain Safe

8 Drugs Taken Off the Market: Important Lessons Learned

Part III: Systemic Drugs for Infectious Diseases

9 Systemic Antibacterial Agents

10 Systemic Antifungal Agents

11 Systemic Antiviral Agents

12 Systemic Antiparasitic Agents

Part IV: Systemic Immunomodulatory Drugs

13 Systemic Corticosteroids

14 Methotrexate

15 Azathioprine

16 Mycophenolates

17 Cyclosporine

18 Phosphodiesterase-4 and Janus Kinase Inhibitors

19 Cytotoxic Agents

20 Dapsone

21 Antimalarial Agents

22 Systemic Retinoids

Part V: Drugs Used in Conjunction with UV or Visible Light

23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities

24 Extracorporeal Photochemotherapy (Photopheresis)

25 Photodynamic Therapy

Part VI: Biologic Therapeutics

26 Tumor Necrosis Factor Inhibitors

27 Interleukin 12/23 Inhibitors

28 Interleukin 17 Inhibitors

29 Interleukin 23 Inhibitors

30 Rituximab

31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

Part VII: Miscellaneous Systemic Drugs

32 Antihistamines

33 Vasoactive and Antiplatelet Agents

34 Antiandrogens and Androgen Inhibitors

35 Psychotropic Agents

36 Intravenous Immunoglobulin Therapy

37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events

38 Hedgehog Pathway Inhibitors

39 Drugs for the Skinternist

40 Miscellaneous Systemic Drugs

Part VIII: Topical Drugs for Infectious Diseases

41 Topical Antibacterial Agents

42 Topical Antifungal Agents

43 Topical and Intralesional Antiviral Agents

44 Topical Antiparasitic Agents

Part IX: Topical Immunomodulatory Drugs

45 Topical Corticosteroids

46 Topical Retinoids

47 Topical and Intralesional Chemotherapeutic Agents

48 Topical Calcineurin Inhibitors

49 Topical Vitamin D3

Part X: Miscellaneous Topical Drugs

50 Sunscreens

51 Therapeutic Shampoos

52 α-Hydroxy Acids

53 Chemical Peels

54 Products for the Care of Chronic Wounds

55 Agents Used for Treatment of Hyperkeratosis

56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents

57 Miscellaneous Topical Agents

Part XI: Injectable and Mucosal Routes of Drug Administration

58 Local Anesthetics

59 Injectable Dermal and Subcutaneous Fillers

60 Botulinum Toxin Injections

61 Oral Mucosal Therapeutics

Part XII: Major Adverse Effects From Systemic Drugs

62 Hepatotoxicity of Dermatologic Drug Therapy

63 Hematologic Toxicity of Drug Therapy

64 Drug-induced Malignancy

65 Dermatologic Drugs During Pregnancy and Lactation

66 Drug Interactions

67 Cutaneous Drug Reactions With Systemic Features

Part XIII: Special Pharmacology and Therapeutics Topics

68 Informed Consent and Risk Management

69 Compounding in Dermatology

70 Dermatologic Drug Therapy in Children

Appendix I Core Questions for Understanding Systemic Dermatologic Drugs

Appendix II The Most Potentially Serious Drug Interactions